736 related articles for article (PubMed ID: 2860558)
1. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
3. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
[TBL] [Abstract][Full Text] [Related]
4. Biochemical profile of risperidone, a new antipsychotic.
Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
[TBL] [Abstract][Full Text] [Related]
5. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.
Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA
J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
Laduron PM; Janssen PF; Gommeren W; Leysen JE
Mol Pharmacol; 1982 Mar; 21(2):294-300. PubMed ID: 6124876
[TBL] [Abstract][Full Text] [Related]
7. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
8. Characterization of solubilized serotonin (S2) receptors in rat brain.
Ilien B; Gorissen H; Laduron PM
Mol Pharmacol; 1982 Sep; 22(2):243-9. PubMed ID: 7144728
[TBL] [Abstract][Full Text] [Related]
9. Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain.
De Souza EB; Kuyatt BL
Synapse; 1987; 1(5):488-96. PubMed ID: 2975068
[TBL] [Abstract][Full Text] [Related]
10. Hypothermia reduces the rate of dissociation of specific ligands from dopamine-D2 and 5-hydroxytryptamine1A receptors in the mouse brain in vivo.
Stenfors C; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):479-86. PubMed ID: 11692232
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of McN-5707 as a potential antidepressant.
Shank RP; Gardocki JF; Schneider CR; Vaught JL; Setler PE; Maryanoff BE; McComsey DF
J Pharmacol Exp Ther; 1987 Jul; 242(1):74-84. PubMed ID: 3039115
[TBL] [Abstract][Full Text] [Related]
12. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region.
Dewar KM; Reader TA; Grondin L; Descarries L
Synapse; 1991 Sep; 9(1):14-26. PubMed ID: 1724575
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
14. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
Lyon RA; Davis KH; Titeler M
Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
16. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
Cohen ML; Schenck KW; Kurz KD
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
[TBL] [Abstract][Full Text] [Related]
17. In vivo binding of [3H]ketanserin on serotonin S2-receptors in rat brain.
Laduron PM; Janssen PF; Leysen JE
Eur J Pharmacol; 1982 Jun; 81(1):43-8. PubMed ID: 7117369
[TBL] [Abstract][Full Text] [Related]
18. Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.
Altar CA; Kim H; Marshall JF
J Pharmacol Exp Ther; 1985 May; 233(2):527-38. PubMed ID: 3889277
[TBL] [Abstract][Full Text] [Related]
19. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
Awouters F; Niemegeers CJ; Megens AA; Janssen PA
J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
